Searchable abstracts of presentations at key conferences in endocrinology

ea0056p140 | Endocrine tumours and neoplasia | ECE2018

Achievement of therapeutic mitotane concentrations in management of advanced adrenocortical cancer: a single centre experience in 47 patients

Bakhit Mohamed , Whitelaw Benjamin C , Gilbert Jackie , Coskeran Patsy , Diaz-Cano Salvador , Taylor David R , Taylor Norman T , Ghatore Lea , Lewis Dylan , Vivian Gillian , Sarker Debashis , Ross Paul , Davis Laura May , Clough Jennifer , Hubbard Johnathan G , Galata Gabriele , Prachalias Andreas , Schulte Klaus-Martin , Aylwin Simon J B

Introduction: Multi-modal therapy for adrenocortical carcinoma (ACC) includes surgery, therapy with the adrenolytic agent mitotane and systemic chemotherapy. Achievement of therapeutic mitotane concentrations (≥14 mg/l) has been related to improved outcomes.Aim: To evaluate the effectiveness of a defined* high dose protocol mitotane therapy in patients with advanced ACC (stages III and IV).Methods: Review of patients presenti...

ea0077op6.2 | Endocrine Cancer and Late Effects | SFEBES2021

The evaluation of a musculoskeletal health package intervention to prevent bone toxicity in women with gynaecological malignancies undergoing pelvic radiotherapy. The RadBone randomised controlled feasibility study

Grigoriadou Victoria Chatzimavridou , Barraclough Lisa , Baricevic-Jones Ivona , Bristow Robert , Eden Martin , Haslett Kate , Johnson Karen , Kochhar Rohit , Merchant Zoe , Moore John , O’Connell Sarah , Taylor Sally , Westwood Thomas , Whetton Anthony , Yorke Janelle , Higham Claire E

Background: Bone toxicity and more specifically Radiotherapy Related Insufficiency Fractures (RRIFs) are common late effects of pelvic radiotherapy, associated with increased morbidity and reduced quality of life, while their cost to the health system is currently unknown. The mechanisms underlying RRIFs are not well understood. Effective preventive techniques and management pathways need to be developed and validated with robust clinical and health economic analyses. The RadB...

ea0077p137 | Adrenal and Cardiovascular | SFEBES2021

Classic and 11-oxygenated androgens in serum and saliva across adulthood and the menstrual cycle – a mass spectrometry-based cross-sectional study

Schiffer Lina , Kempegowda Punith , Adaway Joanne E , Shaheen Fozia , Ebbehoj Andreas , Singh Sumitabh , Prete Alessandro , Hawley James , Sitch Alice J. , Keevil Brian G. , Bancos Irina , Taylor Angela E. , Arlt Wiebke

Background: The gonads are the major source of classic androgens during reproductive years. Additionally, the adrenal gland produces precursors for both classic and 11-oxygenated androgen biosynthesis, with androgen activation predominantly occurring in peripheral target tissues of androgen action. We used liquid chromatography-tandem mass spectrometry to profile classic and 11-oxygenated androgens in serum and saliva across the adult age range and assessed diurnal as well as ...

ea0077p40 | Metabolism, Obesity and Diabetes | SFEBES2021

A randomised controlled pilot trial of oral 11β-HSD1 inhibitor AZD4017 for wound healing in adults with type 2 diabetes mellitus

Ajjan Ramzi , Hensor Elizabeth , Shams Kave , Galdo Francesco Del , Abbas Afroze , Woods Janet , Fairclough Rebecca , Pegg Lindsay , Freeman Adrian , Morgan Ann , Stewart Paul , Taylor Angela , Arlt Wiebke , Tahrani Abd , Russell David , Tiganescu Ana

Chronic wounds (e.g. diabetic foot ulcers) have a major impact on quality of life, yet treatments remain limited. Glucocorticoids impair wound healing; preclinical research suggests that blocking glucocorticoid activation by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) improves wound repair. This investigator-initiated double-blind, randomised, placebo-controlled parallel-group phase 2b pilot trial investigated efficacy, safety and feasibility of 11&...

ea0077p42 | Metabolism, Obesity and Diabetes | SFEBES2021

Chronic inflammation regulates androgen metabolism and exposure in Macrophages

Martin Claire S , Kalirai Matthew Singh , Crastin Ana , Turner Jason D , Schiffer Lina , Gilligan Lorna C , Taylor Angela E , Scheel-Toellner Dagmar , Raza Karim , Filer Andrew , Jones Simon W , Arlt Wiebke , Hewison Martin , Hardy Rowan S

Active androgens exert immunomodulatory actions at sites of inflammation and lower levels are implicated in the increased incidence of rheumatoid arthritis (RA) in females. However, inflammatory regulation of intracrine androgen metabolism within cell populations at sites of inflammation remain poorly defined. In this study we characterised immune and stromal cell androgen metabolism in RA patients and assessed their functional significance. Using the online Accelerating Medic...

ea0078oc4.7 | Oral Communications 4 | BSPED2021

The use of urinary steroid profiles in monitoring therapy in children with 21-hydroxylase deficiency – results from the CAH-UK cohort study

Bacila Irina , Lawrence Neil , Alvi Sabah , Cheetham Timothy , Crowne Elizabeth , Das Urmi , Dattani Mehul , Davies Justin H , Gevers Evelien , Krone Ruth , Kyriakou Andreas , Patel Leena , Randell Tabitha , Ryan Fiona , S Faisal Ahmed , Keevil Brian , Taylor Norman , Krone Nils

Introduction: Monitoring glucocorticoid (GC) replacement in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) remains challenging. There are disease-specific patterns in the plasma and urinary steroid profiles in 21OHD, a key role being played by the 11-oxygenatedC19 androgens. Aim: To explore the urinary steroid profile in 21OHD in relation to treatment and plasma steroids. Methods: Partic...

ea0050oc1.3 | Early Career Oral Communications | SFEBES2017

Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E. , Doig Craig L. , Meimaridou Eirini , Walsh Mark , Jenkinson Carl , Rodriguez-Blanco Giovanny , Jafri Alisha , Ronchi Cristina , Metherell Louise A. , Hebenstreit Daniel , Dunn Warwick B. , Arlt Wiebke , Foster Paul A.

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating NNT mutations lead to isolated primary adrenal insufficiency, suggesting a selective vulnerability of adrenoc...

ea0050oc1.3 | Early Career Oral Communications | SFEBES2017

Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E. , Doig Craig L. , Meimaridou Eirini , Walsh Mark , Jenkinson Carl , Rodriguez-Blanco Giovanny , Jafri Alisha , Ronchi Cristina , Metherell Louise A. , Hebenstreit Daniel , Dunn Warwick B. , Arlt Wiebke , Foster Paul A.

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating NNT mutations lead to isolated primary adrenal insufficiency, suggesting a selective vulnerability of adrenoc...

ea0083ao2 | Adrenal and Cardiovascular | EYES2022

Combining steroid and global metabolome profiling by mass spectrometry with machine learning to investigate metabolic risk in benign adrenal tumours with mild autonomous cortisol secretion

A Prete , L Abdi , M Canducci , A. E. Taylor , L. C. Gilligan , A Albors-Zumel , E van den Brandhof , Y Zhang , K. N. Manolopoulos , P Tino , M Biehl , W. B. Dunn , W Arlt

Background: Benign adrenal tumours are discovered in 3-10% of adults and can be non-functioning (NFAT) or associated with adrenal hormone excess, most frequently mild autonomous cortisol secretion (MACS) defined by the failure to suppress cortisol after 1 mg dexamethasone overnight but lack of distinct signs of Cushing’s syndrome (CS). We found that MACS increases the prevalence and severity of type 2 diabetes and hypertension and primarily affects women (Ann Int Med. 202...

ea0065ec1.2 | Early Career Prize Lecture Translational | SFEBES2019

From bench to bedside and beyond: a novel therapy to improve wound healing in type 2 diabetes

Ajjan Ramzi , Hensor Elizabeth , Abbas Afroze , Galdo Francesco Del , Russell David , Shams Kave , Stewart Paul , Webber Lorraine , Pegg Lindsey , Freeman Adrian , Woods Janet , Eng Sookhoe , Taylor Angela , Arlt Wiebke , Tahrani Abd , Tiganescu Ana

The International Diabetes Federation estimates that type 2 diabetes mellitus (T2DM) will affect 642 million people by 2040. Chronically inflamed, hypoxic wounds are common in T2DM and represent a global unmet clinical need. Each year, diabetic foot ulcers cost the NHS £650 million and cause 1 in 200 UK deaths. This mortality is greater than colon, breast and prostate cancer combined. Glucocorticoids are used to treat a range of inflammatory conditions (e.g. asthma, eczem...